Johnson & Johnson Tops Q2 Earnings Estimates, Boosts FY 2026 Guidance
Johnson & Johnson reported Q2 2026 adjusted EPS of $2.90, beating consensus of $2.85, on revenue of $25.3 billion that topped estimates near $25.0 billion. The company raised its FY2026 guidance to $11.60-$11.75 adjusted EPS and $100.8-$101.4 billion revenue, with Innovative Medicine leading growth.
JNJ reported second-quarter 2026 earnings that topped Wall Street estimates, with adjusted EPS of $2.90 versus a consensus of roughly $2.85, on reported sales that grew 6.6% year-over-year to $25.3 billion, ahead of analyst expectations near $25.0 billion .
Growth was led by the Innovative Medicine segment, where worldwide operational sales rose about 6.8% and reported sales climbed to roughly $16.4 billion, driven by oncology products including DARZALEX, CARVYKTI, TECVAYLI and RYBREVANT/LAZCLUZE, alongside TREMFYA in immunology and SPRAVATO and CAPLYTA in neuroscience. That growth was partially offset by continued erosion in STELARA and REMICADE as biosimilar competition weighs on the older immunology franchise. MedTech delivered steadier, more moderate growth of roughly 3.6% operationally, with wound closure, biosurgery, electrophysiology, Shockwave and Vision products contributing.
On the back of the stronger quarter, Johnson & Johnson raised its full-year 2026 guidance. The company now expects FY2026 adjusted EPS of $11.60 to $11.75, up from prior guidance, versus a consensus estimate around $11.57, and revenue of $100.8 billion to $101.4 billion, edging past the prior roughly $100.9 billion estimate [doc4, doc8].
The upgraded outlook signals management's confidence that its pharmaceutical pipeline can keep offsetting patent-driven declines in legacy drugs, even as the guidance assumes continued execution across a diversified portfolio spanning oncology, immunology, neuroscience and medical devices .
Related Stocks
Powered by SentiSense - Intelligent Market Analysis